Gefapixant

Gefapixant

Chemical structure of Gefapixant

Gefapixant is a pharmaceutical drug that acts as a selective antagonist of the P2X3 receptor. It is primarily being investigated for its potential use in treating chronic cough and other conditions associated with hypersensitivity of the sensory nerves.

Mechanism of Action

Gefapixant works by inhibiting the P2X3 receptor, which is a type of purinergic receptor found on sensory neurons. These receptors are activated by extracellular ATP, which is released during tissue damage or inflammation. By blocking these receptors, gefapixant reduces the activation of sensory neurons, thereby decreasing the sensation of cough.

Clinical Applications

Gefapixant is being studied for its effectiveness in treating chronic cough, a condition characterized by a persistent cough lasting more than eight weeks. Chronic cough can significantly impact a patient's quality of life and is often resistant to traditional treatments. By targeting the P2X3 receptor, gefapixant offers a novel approach to managing this condition.

Development and Trials

Gefapixant is currently undergoing clinical trials to evaluate its safety and efficacy. Early studies have shown promise, with patients experiencing a reduction in cough frequency and severity. Ongoing research aims to further establish its therapeutic potential and determine the optimal dosing regimen.

Side Effects

Common side effects of gefapixant include taste disturbances, such as dysgeusia, which is a distortion of the sense of taste. This side effect is attributed to the drug's action on P2X3 receptors, which are also present in taste pathways.

Related Pages

• Chronic cough
• P2X3 receptor
• Sensory neuron